Biopharma Co. Hit With Suit Over Directors' 'Excessive' Pay

Ultragenyx Pharmaceutical Inc. was hit with a derivative stockholder suit in Delaware Chancery Court on Wednesday, claiming the company's board is being paid "excessive" salaries, even as the company continues to...

Already a subscriber? Click here to view full article